Micronized/ultramicronized palmitoylethanolamide improves depression and fatigue in coronavirus disease 2019 (COVID-19) survivors.

Publication date: Feb 22, 2024

Coronavirus disease 2019 (COVID-19) may lead to neuropsychiatric sequelae. Palmitoylethanolamide (PEA) is an anti-inflammatory and neuroprotective amide used in depressive syndromes. Here we investigate whether micronized/ultramicronized (m/um) PEA improves neuropsychiatric sequelae in COVID-19 survivors. Patients evaluated at our post-COVID-19 outpatient clinic between February and August 2021 and presenting neuropsychiatric manifestations (n = 98) were offered treatment with m/umPEA 600 mg twice daily for 3 months. Those accepting m/umPEA therapy (n = 57) were compared with those who did not (n = 41), in terms of depression, fatigue, chronic pain and subjective well-being, through validated scales administered pre- and posttreatment. The two groups did not differ in terms of demographics, comorbidities, psychiatric history, antidepressant therapy, acute COVID-19 severity and baseline neuropsychiatric status. Patients receiving m/umPEA showed a greater improvement in depression and fatigue (both P 

Concepts Keywords
August Coronavirus
Coronavirus Covid
February Depression
Outpatient Fatigue
Palmitoylethanolamide Improves
Micronized
Neuropsychiatric
Palmitoylethanolamide
Pea
Sequelae
Survivors
Therapy
Ultramicronized
Umpea

Semantics

Type Source Name
drug DRUGBANK Palmidrol
disease MESH coronavirus disease 2019
disease MESH sequelae
disease MESH depressive syndromes
disease MESH chronic pain
disease IDO history
disease MESH Long Covid

Original Article

(Visited 1 times, 1 visits today)